Hepatitis B in sub-Saharan Africa - how many patients need therapy?
Hepatitis B is endemic in sub-Saharan Africa with approximately 60 million people chronically infected. While prevention, through vaccination, is central to elimination strategies, only 11 countries have birth dose vaccination and full vaccine coverage remains at sub-optimal levels. Furthermore, to fully realize elimination, those chronically infected need to be identified and then linked to care and assessed for therapy. Given current treatment criteria, the precise quantum of people warranting therapy, according to criteria, is essentially unknown. The issue is further complicated by data to suggest differences in the numbers of people requiring treatment when applying WHO as compared to European Association for the Study of the Liver, EASL, criteria. Optimal determination of treatment eligibility is further hindered by the lack of available tools to adequately assess individual patients. It is conceivable that accurately determining the number of those requiring treatment, given the heterogeneity of hepatitis B in Africa, is difficult. Better studies and data are required but more significantly, improved access and availability to the tools needed to assess patients as well as access to drugs are as important, if not more important, to achieve elimination.